The Africa medical cannabis market supported by the spread of licensing frameworks for medical cultivation and export across southern Africa, rising demand for cannabinoid-based treatments in pain, epilepsy, cancer, and HIV/AIDS care, and growing investment from international players drawn by favorable climate and low-cost labor. Africa medical cannabis market size increased from USD 1.9 Billion in 2025 to USD 2.3 Billion in 2026. Looking forward, IMARC Group expects the market to reach USD 8.2 Billion by 2034, exhibiting a growth rate (CAGR) of 17.24% during 2026-2034. South Africa alone has seen SAHPRA issue 120 export licenses and the Department of Agriculture issue 1,408 cultivation permits, while the wider hemp and cannabis industry employs over 90,000 people.
How AI is Reshaping the Future of Africa Medical Cannabis Market?
- AI-driven precision agronomy, using sensors, satellite imagery, and predictive models, helps licensed cultivators in high-altitude and sun-rich regions such as Lesotho and Zimbabwe optimize irrigation, nutrients, and harvest timing, improving cannabinoid consistency, a key requirement for pharmaceutical-grade export.
- Machine learning in extraction and quality control supports batch-level monitoring of THC and CBD content, contaminants, and residual solvents, helping producers meet the Good Manufacturing Practice (GMP) standards demanded by European buyers.
- AI-enabled compliance and traceability platforms track plants from seed to shipment, simplifying permit reporting, reducing diversion risk, and speeding up the documentation needed for import and export permits.
- AI-assisted drug discovery and clinical analytics are helping pharmaceutical companies and research centers identify promising cannabinoid formulations for epilepsy, chronic pain, and cancer-related symptoms, shortening development cycles for locally developed products.
- AI-powered demand forecasting and supply chain planning allow exporters to match production volumes with international orders, lowering inventory losses and improving logistics, a notable advantage where shipments are often routed through a single regional hub.
Grab a sample PDF of this report: https://www.imarcgroup.com/africa-medical-cannabis-market/requestsample
Market Growth Factors
The Africa medical cannabis market is driven by the steady expansion of legal frameworks across the continent. Around ten African countries have passed laws allowing production for medical and scientific purposes, including Lesotho, Zimbabwe, South Africa, Uganda, Malawi, Zambia, Ghana, Eswatini, Rwanda, and Morocco. Governments see the sector as a source of rural jobs, export revenue, and foreign investment. In South Africa, the Department of Trade, Industry and Competition is developing a commercialization policy and an overarching Cannabis Bill to unify existing regulations, and the Agricultural Research Council plans a 2,000 square meter climate-controlled cannabis research facility in Pretoria. Licensing economics also shape the competitive field, with Zimbabwe fees ranging from USD 5,000 to USD 50,000 and Uganda requiring USD 5 million in minimum capital and a USD 1 million bank guarantee for cultivation and export authorization.
Export demand is a central growth engine. Africa’s industry is largely export-oriented, targeting European pharmaceutical demand and North American CBD markets where legal demand exceeds domestic supply. Lesotho, for example, offers more than 300 days of sunshine a year at high altitude, which attracted Canopy Growth to acquire a licensed Lesotho operator, and its regulator licenses cultivation, manufacture, import, and export under one framework. To sell in Europe, producers must meet GMP standards, which is pushing investment in extraction, testing, and quality systems. Structural gaps remain, such as the lack of accredited testing laboratories in Lesotho, where samples must be sent to South Africa, and export logistics routed through South African ports, creating opportunities for service providers.
Rising awareness of the medical benefits of cannabinoids is broadening the domestic base. Cannabis-derived medicines are being used to relieve pain and muscle spasms, ease nausea and appetite loss in cancer patients, and manage epilepsy. Zimbabwe has opened its domestic market to CBD as a traditional herbal medicine, expanding beyond export-only production, while South Africa’s private-use legislation signals shifting public attitudes. Proposed regulations under South Africa’s private-use law cap personal possession at 750 grams and cultivation at five plants per adult. This, together with low-cost labor, favorable growing conditions, and international investment, is expected to continue to strengthen the regional supply chain and widen patient access.
Market Segmentation
Species Insights:
- Cannabis Indica
- Sativa
- Hybrid
Indica, sativa, and hybrid strains are cultivated to target different therapeutic profiles, with hybrids increasingly developed for balanced THC and CBD ratios suited to pharmaceutical formulation.
Derivative Insights:
- Cannabidiol
- Tetrahydrocannabinol
- Others
CBD is widely accepted for medical use, with Lesotho capping THC content in CBD products at 0.03%, while THC-based derivatives are used under stricter prescription and permit controls.
Route of Administration Insights:
- Capsules and Oral Solutions
- Vaporizers
- Smoking
- Topicals
- Others
Application Insights:
- Cancer
- HIV/AIDS
- Epilepsy
- Pain
- Others
End User Insights:
- Pharmaceutical Industry
- Research and Development Centers
- Others
Regional Insights:
- Lesotho
- Zimbabwe
- South Africa
- Ghana
- Zambia
- Malawi
Competitive Landscape
Key players in the market include:
- AgriPharma Pty LTD.
- Bophelo Bioscience & Wellness (Pty) Ltd. (Halo Labs Inc)
- Canopy Growth Corporation
- Medigrow Africa
- Medi Kingdom
- MG Health
- Pharmaceutical Development Company
- Precision Extraction Solutions
- Verve Dynamics (Pty) Ltd.
Recent Development & News
- February 2026: South Africa’s Department of Justice and Constitutional Development published draft regulations under the Cannabis for Private Purposes Act, proposing a possession limit of 750 grams and a cap of five plants per adult for private use. The regulations must still be approved by Parliament before the Act is brought into operation.
- May 2024: South Africa’s President signed the Cannabis for Private Purposes Act into law. The Act provides a framework for adult use, possession, and cultivation in private places, and provides for the expungement of certain cannabis-related criminal records, while medical cannabis continues to be regulated under the medicines framework.
- February 2024: South Africa’s Parliament passed the Cannabis for Private Purposes Bill, a step that also strengthened the policy momentum behind the country’s wider hemp and cannabis commercialization plans.
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
Contact Us
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: sales@imarcgroup.com,
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302
